AccuStem Sciences Reports Q2 2026 Financial Results with Improved Net Loss

AccuStem Sciences Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $252,573, a 37% improvement compared to a net loss of $401,403 in the same period of 2025. For the six months ended June 30, 2026, the company recorded a net loss of $738,456, down from $841,811 in the prior year. The company did not generate any revenue during this period, but it recognized $98,400 in other income, attributed to credits against previously recorded research and development expenses.

The company's total operating expenses for the second quarter decreased to $350,973 from $401,403 year-over-year, primarily due to reduced research and development costs, which fell to $43,712 from $60,204. General and administrative expenses also decreased to $307,261 from $341,199, reflecting the absence of payroll-related bonuses in 2026. For the first half of 2026, research and development expenses increased significantly to $163,237, compared to $88,550 in the prior year, largely due to duplicate invoices from a supplier, which were offset by credits.

AccuStem's balance sheet as of June 30, 2026, showed total assets of $1,606,204, an increase from $1,549,446 at the end of 2025. Current assets rose to $106,204, driven by an increase in prepaid expenses. However, total liabilities also increased to $5,723,821 from $4,951,071, primarily due to a rise in related party payables. The company reported an accumulated deficit of $10,521,599, reflecting ongoing operational losses since its inception.

In terms of strategic developments, AccuStem is focused on the commercialization of its proprietary genomic tests, including the MicroRNA Signature Classifier (MSC) and StemPrintER, aimed at improving cancer diagnosis and treatment. The company plans to launch the MSC test for clinical use in early 2027, targeting a market opportunity exceeding $5.5 billion for lung cancer diagnostics. The StemPrintER test, which predicts the risk of recurrence in breast cancer patients, is also in the pipeline, with a potential market of over $800 million.

Looking ahead, AccuStem anticipates continued operating losses as it invests in research and development and seeks additional funding to support its operations. The company is actively pursuing equity financing to address its capital needs, as its current cash balance of $12,928 is insufficient to sustain operations beyond August 2026. Management has acknowledged the need for significant additional cash resources to continue its planned activities and has begun implementing a remediation plan to strengthen its internal controls over financial reporting.